BEARINGPOINT
17.5.2022 08:57:12 CEST | Business Wire | Press release
Management and technology consultancy BearingPoint has created a deep dive study on enterprise data resilience . This paper is the first of five companion pieces to the 2021 ‘Can you thrive under pressure’ study, the analysis of over 5,000 projects leading to the ranking of 150 best practice resilient organizations. BearingPoint has also created a resilience benchmarking tool that enables any organization to assess their own alignment with the five fundamental pillars of resilience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005860/en/
BearingPoint believe data and analytic resilience is undermined by lack of people empowerment, as 65% of organizations lack data literacy and 56% face cultural resistance to change. Other obstacles impacting data led change initiatives included lack of resources and funding (33%) and disconnect with the business strategy (20%). BearingPoint’s study also concludes that implementation is not easy. The study has found that organizations need a structured vision combined with a disciplined approach e.g., an effective data strategy: without it organizations will fail to generate benefits from investment.
BearingPoint’s research indicates that organizations’ data strategy can only be successful if it is underpinned by the five dimensions of a resilient organization:
1. Understand your data ecosystem: You need the right datapoints to take the right decisions
2. Empower your people for change: Make sure your people interact positively in the data value chain
3. Align data centricity with business outcomes: Steer your data journey so it is agile and focused on business outcomes
4. Use technology to improve agility: Select the architecture that will best support your business model
5. Build proper and effective governance: Data-centricity needs to involve your entire organization, not just leadership
Jan Henderyckx, Partner at BearingPoint asks “is data a hobby or holy grail in your organization? We are witnessing the start of a new industrial revolution, fuelled by data rather than coal. But we believe effective data-centric transformation is not about size, but attitude. Our research shows companies will only survive and thrive if they adopt a rounded, well-balanced and progressive approach across these five dimensions. All are vital. Only by delivering on all of them, your organization will become resilient to change. As all firms, in all sectors must understand that data needs to be at the heart of their business strategy.”
All categories of organization type that BearingPoint studied had room for improvement in the area of data resilience with organizations of all types showing maturing or developing data centricity. BearingPoint observed that Government organizations have lower data resilience scores than privately held and publicly listed companies. According to the study, a reason for this may be that privately held companies may have more scope to execute fast decision making (governance).
Jan Henderyckx will be discussing the study’s finding as the Plenary Keynote speaker at: Creating Data Centric Business Resilience at IRMUK Data Governance Conference Europe, May 18, 2022, in London.
“We are living in a world in which it is increasingly more important to be able to adapt to the changing environment. Your decisions should be based on facts rather than assumptions. Companies that put data centricity at the core of their strategy are going to create value. Especially if they apply a comprehensive approach to all dimensions that impact the implementation of a data strategy,’’ says Jan Henderyckx.
About the study
BearingPoint analyzed over 5,000 client projects, built a model to assess how organizations create successful long-term transformations, and then calibrated resilience profiles based on five observed characteristics. You can download the study here to find out more: https://www.bearingpoint.com/en-gb/insights-events/insights/data-must-be-at-the-heart-of-your-business-strategy/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
www.bearingpoint.com
www.linkedin.com/company/bearingpoint
@BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005860/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
